Neuralink's private valuation estimates currently range from $42B to $52.9B as of early October 2026, supported by secondary market trading at approximately $150 per share following its June 2025 Series E round at roughly $9.7B post-money. Recent clinical advances, including reduced daily calibration times for implant users and sustained information rate gains in brain-computer interface performance, have sustained investor interest amid ongoing FDA trials. With the October 31 resolution date approaching, short-term sentiment hinges on any new secondary transactions, funding announcements, or regulatory updates that could shift implied probabilities before month-end, though the company remains pre-revenue and focused on development rather than an IPO.